MEETING MATERIALS
ANNUAL REPORT
View an enhanced version of our Annual Report.
PROXY STATEMENT
View an enhanced version of our Proxy Statement.
View an enhanced version of our Annual Report.
View an enhanced version of our Proxy Statement.
June 17, 2025
8:00 AM PT
10770 Wateridge Circle, Suite 210
San Diego, California 92121
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, a CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889).
Enable broad development of our best-in-class programs targeting co-inhibitory receptors in RA and UC.
Generate in vitro and in vivo translational and clinical data to inform the potential differentiation of our molecules from in-class competitors and standard of care, and identify patient populations most likely to have deeper and/or more durable responses by restoring immune balance.
Facilitate the global commercialization of our programs targeting co-inhibitory receptors while retaining rights in key therapeutic areas and/or commercial markets to enable us to become a fully integrated discovery, development and commercial organization.
Continue to leverage our research platform to generate potentially best-in-class antibodies against high-value immunological targets.